Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn's Disease Initiating Vedolizumab Versus Ustekinumab.

Michael D KappelmanJ D LewisX ZhangF C LinL WeisbeinW ChenJ BurrisJ E DorandL E ParlettK HaynesV NairA F KaulA DobesM D Long

Published in: Digestive diseases and sciences (2023)

Among anti-TNF experienced patients with CD, Pain Interference or Fatigue was not significantly different 4-10 months after starting ustekinumab or vedolizumab. However, reduced steroid use and increased persistence suggest superiority of ustekinumab for non-PRO outcomes.

Keyphrases

patient reported outcomes
rheumatoid arthritis
ulcerative colitis
patients with inflammatory bowel disease
chronic pain
pain management
neuropathic pain
sleep quality
depressive symptoms
metabolic syndrome
nk cells
spinal cord injury